
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
A therapeutic approach to the holiday wish list.
This article was originally posted on December 20, 2017, and has since been updated. -Ed




